James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6
James Sabry and Aviv Regev at Roche and Genentech have been racking up early stage partnerships, tying up with early stage biotechs developing everything from new AI engines to new ways of delivering gene therapy. Now, they’ve signed on with an older player, joining a small molecule biotech that’s already collaborated with many of the biggest names in drug development.
Genentech and X-Chem, a biotech that specializes in DNA-encoded libraries, have signed an agreement that will allow the big biotech to both use their technology to find new molecules and give them an exclusive license on a pre-existing program. Details for that program were undisclosed, as were upfront payment and milestones.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
